Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2016 | short review | Ausgabe 4/2016

memo - Magazine of European Medical Oncology 4/2016

Molecular pathogenesis of chronic myeloid leukemia

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2016
Autor:
Gerald Webersinke

Summary

Chronic myeloid leukemia (CML) is a paradigm for effective targeted therapy and is characterized by the hallmark BCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2016

memo - Magazine of European Medical Oncology 4/2016 Zur Ausgabe